ED Coding & Reimbursement Alert - 2003 Issue 10
MEDICARE REFORM: Grassley Provisions Unpopular With Many
Subscribe or sign in to view the full article.
Article Overview
This article discusses a Medicare reform controversy involving oncology payment policy, with attention to drug reimbursement, average wholesale price (AWP), practice expenses, and access concerns raised by the cancer community and medical practice advocates. It is aimed at readers tracking healthcare policy, oncology reimbursement, and physician practice management issues.
Why This Topic Matters
It provides context for Medicare payment reform discussions that can affect oncology practices, drug reimbursement policy, and patient access to care.
What You Will Learn
- How Medicare reform discussions are affecting oncology reimbursement policy
- Why drug payment and practice expense issues are being discussed together
- Which stakeholder groups are concerned about the potential impact on access and practice finances
- How medical practice advocates are framing the policy debate
Who Should Read This
- Oncology providers
- Medical practice administrators
- Healthcare policy professionals
- Coding and reimbursement staff
- Patient advocacy stakeholders
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com